AMRN

Amarin Corporation plc

11.95 USD

Last updated Oct 9, 04:10 UTC

Yesterday HIGH

$12.05

Yesterday LOW

$11.86

52w HIGH

$20.9

52w LOW

$11.83

EPS

0.00

PE

0.00

Next Earnings

Oct 28, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Amarin Corporation plc stock is down -16.96% since 30 days ago. The next earnings date is Oct 28, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 38.24% of the previous 33 October’s closed higher than September. In the last 3 Unusual Options Trades, there were 3 CALLs.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

19 Aug 13:30	19 Mar, 2027	14.00	CALL	100	0
19 Aug 13:35	19 Mar, 2027	14.00	CALL	100	0
03 Sep 13:30	19 Mar, 2027	14.00	CALL	150	204

Advanced Data Unlock

Benzinga Newsdesk

Fri Aug 28, 2026

Amarin Says REDUCE-IT Post Hoc Analysis Showed About 30% Relative Risk Reduction In Major Adverse Cardiovascular Events Among Patients On Icosapent Ethyl At Least 1.5 Years; Hazard Ratio Of 0.73 Persisted After Discontinuation
Benzinga Newsdesk

Fri Aug 21, 2026

JP Morgan Reinstates Underweight on Amarin Corp, Announces $13 Price Target

JP Morgan analyst Jessica Fye reinstates Amarin Corp (NASDAQ:AMRN) with a Underweight and announces $13 price target.
Benzinga Newsdesk

Wed Jul 29, 2026

Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate

Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $42.211 million which missed the analyst consensus estimate of $44.550 million by 5.25 percent. This is a 41.97 percent decrease over sales of $72.740 million the
Benzinga Insights

Tue Jul 7, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay Diagnostics
Benzinga Newsdesk

Tue Jun 30, 2026

Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dL

Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) therapies for the
Benzinga Newsdesk

Thu Jun 4, 2026

U.S. Supreme Court Rules In Favor Of Hikma Pharmaceuticals V Amarin Pharmaceuticals Over Patent Infringement Claims By Amarin

https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf
Benzinga Newsdesk

Wed May 27, 2026

Amarin Announces New Data From A Post Hoc Analysis Of The REDUCE-IT Trial; Apolipoprotein B More Effectively Identified Individuals At Increased Residual Cardiovascular Risk

Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial
Benzinga Insights

Wed Apr 29, 2026

Earnings Scheduled For April 29, 2026
Benzinga Newsdesk

Wed Apr 29, 2026

Amarin Corp Q1 Sales $45.132M Beat $43.771M Estimate

Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $45.132 million which beat the analyst consensus estimate of $43.771 million by 3.11 percent. This is a 7.41 percent increase over sales of $42.017 million the same